Boston Scientific announced a definitive agreement to acquire thrombectomy specialist Penumbra in a cash-and-stock transaction valued at $14.5 billion. Under the deal, Penumbra shareholders will receive approximately 73% cash and 27% equity in the combined company. The acquisition provides Boston Scientific with immediate entry into fast-growing neurovascular and peripheral vascular segments, bolstering its interventional portfolio. Penumbra reported preliminary fourth-quarter 2025 revenue growth of 21–24%, driven by strong demand for its reperfusion and aspiration systems. Boston Scientific expects the deal to dilute earnings by 6–8 cents per share in the first year, moving toward neutral to accretive results thereafter. The transaction, subject to regulatory approval, is projected to close in 2026 and is viewed as a strategic step to reinforce Boston Scientific’s position in minimally invasive therapies.

On January 14, 2026, Citigroup upgraded Boston Scientific to a Buy rating, citing the company’s improving profit margins and favorable product mix. Growth in high-margin franchises such as electrophysiology and the WATCHMAN left atrial appendage closure system has driven expansion in earnings quality and cash flow stability. Hospitals’ increased capital expenditures and normalization of procedural volumes support further margin improvement. In parallel, Boston Scientific unveiled a definitive agreement to acquire Valencia Technologies, a urology specialist known for its eCoin System for overactive bladder. This move is expected to enhance the company’s footprint in urology and address a U.S. patient population of nearly 30 million adults with bladder dysfunction. Investors view these strategic initiatives as key drivers for long-term revenue diversification and profitability.